{"SPADE_N_14428": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_14428", "Peptide Name": "TC-14 (TC-33 analog, synthetic AMPs, Lys-rich, XXA, UCLL1c)", "Source": "sequence truncation, mammal cathelicidin analog, animal-derived, natural derivative", "Family": "Not found", "Gene": "Not found", "Sequence": "KIGQKIKNFFRKLL", "Sequence Length": 14, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 1733.15, "PI": 11.33, "Hydrophobicity": -0.38, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Chenxi Li, Ying Cai, Lin Luo, Gengzhou Tian, Xingyu Wang, An Yan, Liunan Wang, Sijing Wu, Zhongxiang Wu, Tianyu Zhang, Wenlin Chen, Zhiye Zhang, 2024", "Reference": "iScience. 2024 Jun 28;27(7):110404. doi: 10.1016/j.isci.2024.110404.SciDirect", "Title": "TC-14, a cathelicidin-derived antimicrobial peptide with broad-spectrum antibacterial activity and high safety profile"}], "Frequent Amino Acids": "KFI", "Absent Amino Acids": "ACDEHMOPSTUVWY", "Basic Residues": 5, "Acidic Residues": 0, "Hydrophobic Residues": 6, "Polar Residues": 7, "Positive Residues": 5, "Negative Residues": 0, "Net Charge": 5, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (63.16%) toCRAMP-18K: 29%, I=L=F: 14%.Activity: Active against E. coli ATCC8739 (MIC 9.38 ug/ml), A. baumannii ATCC19606 (MIC 2.34 ug/ml), P. aeruginosa ATCC27853 (MIC 9.38 ug/ml), and S. aureus ATCC6538 (MIC 4.68 ug/ml).Structure: random coil in water and helical in 8 mM SDS micelles (74%).In vitro toxicity: human RBC: no hemolysis at 100 ug/ml, not hemo.lytic. Not toxic to HaCaT cells at 100 ug/ml.MOA:bacteria: permeabilized membranes of E. coli, A. baumannii, S. aureus, P. aeruginosa.Resistance development:no:bacteria:P. aeruginosa 27853: P. aeruginosa 27853 and Resistance development:no:bacteria:S. aureus 6538 did not become resistant after 60 passages (generations), but control colistin or vancomycin did.In vivo toxiity: IV injection to mice at 10 mg/kg did not lead to observable toxicity.Animal model:mouse: it could reduce S. aureus or A. baumannii burden dose-dependently in a murine skin wound model.Updated 12/2024", "Similar Sequences": [{"SPADE_ID": "SPADE_N_08845", "Similarity": 1.0, "Sequence": "KIKEKLKKIGQKI"}, {"SPADE_ID": "SPADE_N_15510", "Similarity": 1.0, "Sequence": "LLRRGGEKLAEKFEKIGQKIKNFFRKLLPETES"}, {"SPADE_ID": "SPADE_UN_08130", "Similarity": 1.0, "Sequence": "RKRLRKFRNKIKEKLKKIGQKI"}]}}}